{"name":"SAGE Category","title":"","children":[{"id":"cancer_cell","name":"cancer_cell","presenterLast":"cancer_cell","children":[{"id":"583","name":"583","title":"The CDK4/6 inhibitor abemaciclib induces synergistic immune activation and anti-tumor efficacy in combination with PD-L1 blockade","presenterFirst":"David","presenterLast":"Schaer","presenterInstitution":"Eli Lilly","keywords":"Cyclin-dependent kinase inhibitor;Cancer immunotherapy;Cancer immunotherapy;PD-L1","target":"CDK4/6","tumor":"Colorectal","combo":null,"sage":"cancer_cell","pharma":"pharma"},{"id":"5590","name":"5590","title":"Combination of an oncokinase inhibitor merestinib with anti-PD-L1 results in enhanced immune mediated antitumor activity in CT26 murine tumor model","presenterFirst":"Sau-Chi","presenterLast":"Yan","presenterInstitution":"Eli Lilly and Company","keywords":"Immunotherapy;immune checkpoint PD-L1;immune checkpoint PD-L1;Preclinical testing","target":"Many","tumor":"Many","combo":null,"sage":"cancer_cell","pharma":"pharma"},{"id":"2016","name":"2016","title":"Novel dual cIAP1/XIAP antagonist ASTX660 activity in preclinical models of human papillomavirus(+) and (-) head and neck squamous cell carcinoma","presenterFirst":"Roy","presenterLast":"Xiao","presenterInstitution":"National Institutes of Health","keywords":"Head and neck cancers;IAP;IAP;Tumor necrosis factor [alpha]","target":"SMAC","tumor":"Head_Neck","combo":null,"sage":"cancer_cell","pharma":"academia"},{"id":"5662","name":"5662","title":"MEK inhibitors potentiate tumor immune surveillance by enhancing cancer cell response of IFN\u03b3","presenterFirst":"Mengyu","presenterLast":"Xie","presenterInstitution":"Moffitt Cancer Center","keywords":"MEK Inhibitor;Tumor immunity;Tumor immunity;Chemokines","target":"MEK","tumor":"Many","combo":null,"sage":"cancer_cell","pharma":"academia"},{"id":"2637","name":"2637","title":"Anti-tumor activity of cisplatin is enhanced by PD-1 blockade in preclinical models of head and neck squamous cell carcinoma","presenterFirst":"Nicole","presenterLast":"Schmitt","presenterInstitution":"Johns Hopkins University and NIDCD","keywords":"Cisplatin;Head and neck squamous cell carcinoma;Head and neck squamous cell carcinoma;NA","target":"chemo","tumor":"Head_Neck","combo":null,"sage":"cancer_cell","pharma":"academia"},{"id":"2660","name":"2660","title":"PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model","presenterFirst":"Zhengyu","presenterLast":"Jin","presenterInstitution":"Peking Union Medical College Hospital, Chinese Academy of Medical Sciences","keywords":"Breast cancer;Zoledronic acid;Zoledronic acid;Checkpoint inhibitior","target":"zoledronic_acid","tumor":"Breast","combo":null,"sage":"cancer_cell","pharma":"academia"},{"id":"2632","name":"2632","title":"4SC-202 induces inflamed tumor microenvironment, strongly enhances tumor infiltration with cytotoxic T cells and primes tumors for anti-PD1/PD-L1 therapy","presenterFirst":"Svetlana","presenterLast":"Hamm","presenterInstitution":"4SC","keywords":"Tumor microenvironment;Histone deacetylase inhibitor;Histone deacetylase inhibitor;NA","target":"HDAC","tumor":"Hematological","combo":null,"sage":"cancer_cell","pharma":"pharma"},{"id":"2004","name":"2004","title":"Epigenetic targeting of CD276 expression in medullolbastoma","presenterFirst":"Swapna","presenterLast":"Asuthkar","presenterInstitution":"University of Illinois College of Medicine at Peoria","keywords":"Medulloblastoma;Epigenetics;Epigenetics;EZH2","target":"EZH2","tumor":"Medulloblastoma","combo":null,"sage":"cancer_cell","pharma":"academia"},{"id":"2654","name":"2654","title":"Resveratrol and piceatannol synergistically induce PDL1 expression","presenterFirst":"Justin","presenterLast":"Lucas","presenterInstitution":"Pfizer/New York Medical College","keywords":"Immunotherapy;Resveratrol;Resveratrol;NA","target":"phytochemicals","tumor":"Breast","combo":null,"sage":"cancer_cell","pharma":"pharma"},{"id":"960","name":"960","title":"Mechanisms underlying primary ibrutinib sensitivity in CLL","presenterFirst":"Shih-Shih","presenterLast":"Chen","presenterInstitution":"The Feinstein Institute for Medical Research","keywords":"Chronic lymphocytic leukemia;Bcl-2 protein family;Bcl-2 protein family;Drug sensitivity","target":"CXCR4","tumor":"Hematological","combo":null,"sage":"cancer_cell","pharma":"academia"},{"id":"652","name":"652","title":"PD-L1 and MHC class 1 expression levels are modulated by MEK inhibition on head and neck squamous cell carcinoma","presenterFirst":"Seong-Ho","presenterLast":"Kang","presenterInstitution":"Cancer Research Institute, Seoul National University","keywords":"Head and neck squamous cell carcinoma;HLA Class I;HLA Class I;Immunomodulation","target":"MEK","tumor":"Head_Neck","combo":null,"sage":"cancer_cell","pharma":"academia"},{"id":"1059","name":"1059","title":"Enhanced anti-tumor efficacy of a checkpoint inhibitor in combination with the HDAC inhibitor belinostat in a murine hepato-cellular carcinoma preclinical model","presenterFirst":"Perrine","presenterLast":"Pivette","presenterInstitution":"Onxeo","keywords":"Immunotherapy;Hepatocellular carcinoma;Hepatocellular carcinoma;Antitumor effect","target":"HDAC","tumor":"Hepatocarcinoma","combo":null,"sage":"cancer_cell","pharma":"pharma"},{"id":"2330","name":"2330","title":"BI5: a novel SMAC mimetic that triggers tumor cell death and potentiates PD-1 mediated cancer therapy","presenterFirst":"Markus","presenterLast":"Reschke","presenterInstitution":"Boehringer Ingelheim","keywords":"IAP;Immunomodulation;Immunomodulation;Innate immunity","target":"SMAC","tumor":"Many","combo":null,"sage":"cancer_cell","pharma":"pharma"},{"id":"5603","name":"5603","title":"Melanoma PD1 expression is upregulated by MAPK inhibitors leading to an immune-independent synergism with anti-PD1 antibodies","presenterFirst":"Dario","presenterLast":"Sangiolo","presenterInstitution":"University of Torino, Candiolo Cancer Institute IRCCS","keywords":"melanoma;Targeted therapy;Targeted therapy;NA","target":"MEK","tumor":"Melanoma","combo":null,"sage":"cancer_cell","pharma":"academia"},{"id":"3656","name":"3656","title":"Implication for checkpoint therapeutics: Expression of co-stimulatory and co-inhibitory molecules in melanoma cells","presenterFirst":"Rachana","presenterLast":"Maniyar","presenterInstitution":"New York Medical College","keywords":"Immunomodulation;Combination therapy;Combination therapy;Target discovery","target":"BRAF","tumor":"Melanoma","combo":null,"sage":"cancer_cell","pharma":"academia"},{"id":"630","name":"630","title":"Inactivation of DNA repair triggers dynamic neoantigen evolution and impairs cancer growth","presenterFirst":"Giovanni","presenterLast":"Germano","presenterInstitution":"Candiolo Cancer Institute","keywords":"Immune response;DNA repair;DNA repair;Colorectal cancer","target":"chemo","tumor":"Colorectal","combo":null,"sage":"cancer_cell","pharma":"academia"},{"id":"5591","name":"5591","title":"Mek/erk inhibition enhances anti-pd-l1 effects on the susceptibility to NK cytotoxicity of cisplatin-resistant non-small cell lung cancer","presenterFirst":"Soo Ok","presenterLast":"Lee","presenterInstitution":"Univ. of Rochester Medical Ctr.","keywords":"Natural killer cells;Lung cancer: non-small cell;Lung cancer: non-small cell;NA","target":"MEK","tumor":"Lung","combo":null,"sage":"cancer_cell","pharma":"academia"},{"id":"607","name":"607","title":"PDL1 Expression Associated with Triple Negative Breast Ductal Carcinomas in African American Women","presenterFirst":"Farhan","presenterLast":"Khan","presenterInstitution":"Howard University Hospital","keywords":"African American;NA;NA;NA","target":"PI3K","tumor":"Breast","combo":null,"sage":"cancer_cell","pharma":"academia"},{"id":"2686","name":"2686","title":"Dual inhibition of BCR and TLR signaling has therapeutic potential in chronic lymphocytic leukemia","presenterFirst":"Eman","presenterLast":"Dadashian","presenterInstitution":"NIH/NHLBI","keywords":"Chronic lymphocytic leukemia;Tumor microenvironment;Tumor microenvironment;NA","target":"IRAK","tumor":"Leukemia","combo":null,"sage":"cancer_cell","pharma":"academia"},{"id":"643","name":"643","title":"Induced MHCII expression on breast cancer cells broadens the responding T cell repertoire, delays tumor-specific T cell exhaustion, and impairs tumor growth","presenterFirst":"Tyler","presenterLast":"McCaw","presenterInstitution":"University of Alabama at Birmingham","keywords":"T cell;MHC II;MHC II;Histone deacetylase inhibitor","target":"HDAC","tumor":"Breast","combo":null,"sage":"cancer_cell","pharma":"academia"},{"id":"4713","name":"4713","title":"Deubiquitination and stabilization of programmed cell death-ligand 1 by CSN5","presenterFirst":"Seung-Oe","presenterLast":"Lim","presenterInstitution":"UT MD Anderson Cancer Center","keywords":"Immunotherapy;Inflammation;Inflammation;CSN5","target":"CSN5","tumor":"NA","combo":null,"sage":"cancer_cell","pharma":"academia"},{"id":"637","name":"637","title":"The class I HDAC inhibitor mocetinostat augments checkpoint inhibitor therapy via direct up regulation of antigen presentation transcriptional programs in tumor cells and increased T-cell clonality in tumors","presenterFirst":"David","presenterLast":"Briere","presenterInstitution":"Mirati Therapeutics","keywords":"Histone deacetylase inhibitor;MHC II;MHC II;T cell","target":"HDAC","tumor":"Many","combo":null,"sage":"cancer_cell","pharma":"pharma"},{"id":"3022","name":"3022","title":"Novel Hydrocarbon Stapled Peptide inhibitors Suppresses \u03b2-catenin Dependent Cancer Growth and Immunomodulates Colorectal Tumors","presenterFirst":"David","presenterLast":"Zhu","presenterInstitution":"WntRx/Lab Central","keywords":"Wnt pathway;Immunomodulation;Immunomodulation;Colorectal cancer","target":"beta_catenin","tumor":"Colorectal","combo":null,"sage":"cancer_cell","pharma":"academia"}]},{"id":"immune_effector","name":"immune_effector","presenterLast":"immune_effector","children":[{"id":"2619","name":"2619","title":"Combination of ECP1014 and anti-PD-L1 reduces tumor growth in the CT26 Murine Colon Carcinoma Model of a Cold Tumor","presenterFirst":"Bobby","presenterLast":"Sandage","presenterInstitution":"Euclises Pharmaceuticals, Inc.","keywords":"Combination therapy;Tumor microenvironment;Tumor microenvironment;Colorectal","target":"COX2","tumor":"Colorectal","combo":null,"sage":"immune_effector","pharma":"pharma"},{"id":"1071","name":"1071","title":"Efficacy of trifluridine/tipiracil + anti-mouse PD-1 antibody combination on mouse colorectal cancer model and related tumor immunomodulatory effects","presenterFirst":"Hiroshi","presenterLast":"Tsukihara","presenterInstitution":"Taiho pharmaceutical CO., LTD.","keywords":"Cancer immunotherapy;Colorectal cancer;Colorectal cancer;Xenografts","target":"chemo","tumor":"Colorectal","combo":null,"sage":"immune_effector","pharma":"pharma"},{"id":"2994","name":"2994","title":"Engineered STING targeting immunotherapy delays B16 melanoma tumor growth and significantly improves animal survival as compared to an immune-checkpoint inhibitor","presenterFirst":"Andrea","presenterLast":"Amalfitano","presenterInstitution":"Michigan State University","keywords":"Immunotherapy;AdVCA0848;AdVCA0848;STING agonist","target":"STING","tumor":"Melanoma","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"2993","name":"2993","title":"STING signaling in breast tumor microenvironment modulates immune checkpoint blockade efficacy in the neu-N mouse model of breast cancer","presenterFirst":"Jeremy","presenterLast":"Foote","presenterInstitution":"Johns Hopkins University, School of Medicine","keywords":"Immunotherapy;Checkpoint;Checkpoint;NA","target":"STING","tumor":"Breast","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"4358","name":"4358","title":"The immunomodulatory anti-cancer agent, RRx-001, induces a vaccine-like interferon response through epigenetic induction of viral mimicry","presenterFirst":"Susan","presenterLast":"Knox","presenterInstitution":"Stanford University School of Medicine","keywords":"Immunomodulation;Interferons;Interferons;NA","target":"DNMT","tumor":"Colorectal","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"167","name":"167","title":"Ibrutinib regulates tumor microenvironment and enhances response to everolimus in renal cell carcinoma mouse models","presenterFirst":"Jun","presenterLast":"Chen","presenterInstitution":"Pharmacyclics, LLC, an AbbVie Company","keywords":"Renal cell carcinoma;ibrutinib;ibrutinib;everolimus","target":"BTK","tumor":"Renal","combo":null,"sage":"immune_effector","pharma":"pharma"},{"id":"3998","name":"3998","title":"Alerting the immune system by removing epigenetic silencing of Th1 chemokines","presenterFirst":"Heather","presenterLast":"Sonnemann","presenterInstitution":"NIH","keywords":"Chemokines;NA;NA;NA","target":"DNMT","tumor":"Brain","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"4697","name":"4697","title":"Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment and holds potential for combination with immune checkpoint inhibitors","presenterFirst":"Stefanie","presenterLast":"Mullins","presenterInstitution":"MedImmune","keywords":"Tumor microenvironment;NA;NA;NA","target":"TLR7/8","tumor":"NA","combo":null,"sage":"immune_effector","pharma":"pharma"},{"id":"5584","name":"5584","title":"PHY906(YIV-906), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Immune checkpoint blockade therapy: anti-PDL1, anti-PD1, anti-PD1/CTLA4 against melanoma.","presenterFirst":"Wing","presenterLast":"Lam","presenterInstitution":"Yale Univ. School of Medicine. Dept. of Pharmacology","keywords":"Immunotherapy;Adjuvant;Adjuvant;Immunomodulation","target":"Other","tumor":"Melanoma","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"641","name":"641","title":"PEGylated recombinant hyaluronidase PH20 (PEGPH20) enhances tumor infiltrating CD8<sup>+ </sup>T cell accumulation and improves checkpoint inhibitor efficacy in murine syngeneic breast cancer models","presenterFirst":"Renee","presenterLast":"Clift","presenterInstitution":"Halozyme Theraputics, Inc.","keywords":"Tumor microenvironment;Breast cancer;Breast cancer;T cell","target":"Hyaluronan","tumor":"Breast","combo":null,"sage":"immune_effector","pharma":"pharma"},{"id":"1604","name":"1604","title":"NKTR-214 synergizes with radiotherapy to drive tumor regression","presenterFirst":"Michael","presenterLast":"Mcnamara","presenterInstitution":"Earle A. Chiles Research Institute, Providence Portland Medical Ctr.","keywords":"Immunotherapy;Cytokines;Cytokines;Interleukin-2","target":"IL2","tumor":"NA","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"1676","name":"1676","title":"EZH2 inhibitors in immunotherapy of melanoma","presenterFirst":"Peter","presenterLast":"Hersey","presenterInstitution":"Univ. of  Sydney","keywords":"melanoma;Immunomodulation;Immunomodulation;EZH2","target":"EZH2","tumor":"Melanoma","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"4607","name":"4607","title":"Specific inhibition of PGE<sub>2</sub>-EP4 signaling by E7046 promotes anti-tumor activity of checkpoint blockade agents through boosting cytotoxic T cell activity","presenterFirst":"Diana","presenterLast":"Albu","presenterInstitution":"Eisai Andover Innovative Medicines Institute","keywords":"Prostaglandin E2;Checkpoint blockade;Checkpoint blockade;antigen-specific CTL","target":"PGE-EP4","tumor":"Many","combo":null,"sage":"immune_effector","pharma":"pharma"},{"id":"591","name":"591","title":"Efficacy of ALKS 4230, a novel immunotherapeutic agent, in murine syngeneic tumor models alone and in combination with immune checkpoint inhibitors","presenterFirst":"Heather","presenterLast":"Losey","presenterInstitution":"Alkermes","keywords":"Immunotherapy;Cytokines;Cytokines;NA","target":"IL2","tumor":"Many","combo":null,"sage":"immune_effector","pharma":"pharma"},{"id":"5628","name":"5628","title":"Trilaciclib (G1T28), a CDK4/6 inhibitor, enhances the efficacy of combination chemotherapy and immune checkpoint inhibitor treatment in preclinical models","presenterFirst":"Jessica","presenterLast":"Sorrentino","presenterInstitution":"G1 Therapeutics, Inc","keywords":"Cell cycle inhibitors;Immunotherapy;Immunotherapy;Chemotherapy response","target":"CDK4/6","tumor":"NA","combo":null,"sage":"immune_effector","pharma":"pharma"},{"id":"3682","name":"3682","title":"Synergistic immunostimulatory effects and therapeutic benefit of combined histone deacetylase and bromodomain inhibition in non-small cell lung cancer","presenterFirst":"Dennis","presenterLast":"Adeegbe","presenterInstitution":"Dana Farber Cancer Institute","keywords":"Histone deacetylase inhibitor;Lung cancer non small cell;Lung cancer non small cell;Immunomodulation","target":"HDAC6","tumor":"Lung","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"5659","name":"5659","title":"Local treatment with novel TLR9 agonist IMO-2125 demonstrates antitumor activity in preclinical models of pancreatic cancer","presenterFirst":"Daqing","presenterLast":"Wang","presenterInstitution":"Idera Pharmaceuticals, Inc.","keywords":"Tumor microenvironment;Immunotherapy;Immunotherapy;Immunomodulation","target":"TLR9","tumor":"Pancreatic","combo":null,"sage":"immune_effector","pharma":"pharma"},{"id":"1634","name":"1634","title":"CDK4/6 inhibition directly enhances an anti-tumor immune response in breast cancer","presenterFirst":"Molly","presenterLast":"DeCristo*","presenterInstitution":"Brigham and Women's Hospital","keywords":"Cyclin-dependent kinase inhibitor;Immune response;Immune response;T cell exhaustion","target":"CDK4/6","tumor":"Breast","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"1617","name":"1617","title":"Mechanistic modeling of a new kinetically-controlled CD122 agonist for cancer immunotherapy: NKTR-214 pharmacokinetics, pharmacodynamics, and receptor pharmacology","presenterFirst":"Samira","presenterLast":"Khalili","presenterInstitution":"Nektar Therapeutics","keywords":"Immunotherapy;Modeling;Modeling;T cell","target":"IL2","tumor":"NA","combo":null,"sage":"immune_effector","pharma":"pharma"},{"id":"5673","name":"5673","title":"Large established B16 tumors in mice are eradicated by ZVex\u00ae (dendritic cell-targeting lentiviral vector) and G100 (TLR4 agonist) combination immunotherapy through increasing tumor-infiltrating effector T cells and inducing antigen spreading","presenterFirst":"Tina","presenterLast":"Albershardt","presenterInstitution":"Immune Design","keywords":"Dendritic cells;Immunotherapy;Immunotherapy;T cell","target":"TLR4","tumor":"Ovarian","combo":null,"sage":"immune_effector","pharma":"pharma"},{"id":"1650","name":"1650","title":"Targeting CD47- SIRP\u03b1 interaction by novel peptide-based antagonists","presenterFirst":"Murali","presenterLast":"Ramachandra","presenterInstitution":"Aurigene Discovery Technologies Ltd.","keywords":"Cancer immunotherapy;Peptides;Peptides;Macrophages","target":"CD47-SIRP","tumor":"Many","combo":null,"sage":"immune_effector","pharma":"pharma"},{"id":"4704","name":"4704","title":"Long-lived de novo DNA methylation programming enforces terminal T-cell exhaustion","presenterFirst":"Hazem","presenterLast":"Ghoneim","presenterInstitution":"St. Jude Children's Research Hospital","keywords":"DNA methylation;Cancer immunotherapy;Cancer immunotherapy;Epigenetics","target":"DNMT","tumor":"NA","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"1636","name":"1636","title":"Increased expression of programmed death-ligand 1 (PD-L1) on infiltrating immune cells of hepatocellular carcinoma (HCC) tissues after sorafenib treatment","presenterFirst":"Li-Chun","presenterLast":"Lu","presenterInstitution":"National Taiwan Univ. Hospital","keywords":"Hepatocellular carcinoma;sorafenib;sorafenib;macrophage","target":"VEGFR","tumor":"Hepatocarcinoma","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"5172","name":"5172","title":"E7386, an Orally Active CBP/beta-catenin Modulator, Induces T Cells Infiltration into Tumor and Enhances Antitumor Activity of Anti-PD-1 mAb in Wnt1 Tumor Syngeneic Mice Model","presenterFirst":"Yusaku","presenterLast":"Hori","presenterInstitution":"Eisai Co., Ltd,","keywords":"Wnt pathway;PD-1;PD-1;Tumor microenvironment","target":"CBP/beta-catenin","tumor":"Melanoma","combo":null,"sage":"immune_effector","pharma":"pharma"},{"id":"3699","name":"3699","title":"Activation of NK cells cytotoxicity mediated by alveolar macrophages in the lung against murine melanoma metastases by combined aerosol immunotherapy","presenterFirst":"Michele","presenterLast":"Sommariva","presenterInstitution":"University of Milan","keywords":"Natural killer cells;Immunostimulation;Immunostimulation;Tumor metastases","target":"TLR","tumor":"Melanoma","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"4928","name":"4928","title":"Impact of <i>E. hirae</i> on the tumoricidal activity of cyclophosphamide","presenterFirst":"Romain","presenterLast":"DAILLERE","presenterInstitution":"Gustave Roussy","keywords":"Chemotherapy;Bacterial treatment;Bacterial treatment;NA","target":"NOD2","tumor":"NA","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"2669","name":"2669","title":"Antitumor activity of the CMP-001 (TLR9 agonist) alone or combined with immune modulators in syngeneic tumor models","presenterFirst":"Sylvie","presenterLast":"MAUBANT","presenterInstitution":"Oncodesign S.A.","keywords":"Inhibitors;Checkpoint;Checkpoint;Antibody","target":"TLR9","tumor":"Many","combo":null,"sage":"immune_effector","pharma":"pharma"},{"id":"1704","name":"1704","title":"UPR signaling promotes T-cell dysfunction to prevent immune-mediated cancer cell killing and immune checkpoint therapy resistance","presenterFirst":"Yismeilin","presenterLast":"Feliz Mosquea","presenterInstitution":"Wake Forest University","keywords":"Immune response;Checkpoint;Checkpoint;Immunotherapy","target":"PERK","tumor":"Melanoma","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"621","name":"621","title":"Tumor suppressor TUSC2 immunogene therapy is synergistic with anti-PD1 in lung cancer syngeneic mouse models","presenterFirst":"Ismail","presenterLast":"Meraz","presenterInstitution":"UT MD Anderson Cancer Ctr.","keywords":"Tumor suppressor gene;Checkpoint;Checkpoint;NA","target":"TUSC2","tumor":"Lung","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"5592","name":"5592","title":"Metformin improves immune function of exhausted peripheral CD8<sup>+</sup> T cells derived from cancer patients.","presenterFirst":"Mototsugu","presenterLast":"Watanabe","presenterInstitution":"Okayama University","keywords":"Immunomodulation;Metabolism;Metabolism;NA","target":"AMPK","tumor":"NA","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"4698","name":"4698","title":"Immuno-oncological efficacy of RXDX-106, a novel, selective and potent small molecule TAM (TYRO3, AXL, MER) inhibitor","presenterFirst":"Gary","presenterLast":"Li","presenterInstitution":"Ignyta, Inc.","keywords":"Immunotherapy;Macrophages;Macrophages;Targeted therapy","target":"TAM","tumor":"Many","combo":null,"sage":"immune_effector","pharma":"pharma"},{"id":"1703","name":"1703","title":"A novel tumor vaccine platform: direct conjugation of antigens to the \u03b2 glucan PAMP Imprime PGG enhances antigen presentation and T cell priming","presenterFirst":"Michael","presenterLast":"Danielson","presenterInstitution":"Biothera Pharmaceuticals, Inc.","keywords":"Vaccines;Innate immunity;Innate immunity;Immunomodulation","target":"PAMP","tumor":"Many","combo":null,"sage":"immune_effector","pharma":"pharma"},{"id":"4696","name":"4696","title":"Development of an inhaled TLR9 agonist for the immunotherapy of lung cancer","presenterFirst":"Robert","presenterLast":"Coffman","presenterInstitution":"Dynavax Technologies","keywords":"Checkpoint;Immunotherapy;Immunotherapy;NA","target":"TLR9","tumor":"Lung","combo":null,"sage":"immune_effector","pharma":"pharma"},{"id":"5576","name":"5576","title":"BPM 31510, a clinical stage candidate demonstrates potent anti-tumor effect in an immune-competent syngeneic pancreatic cancer model","presenterFirst":"Shiva","presenterLast":"Kazerounian","presenterInstitution":"BERG, LLC","keywords":"Immune response;NA;NA;NA","target":"Other","tumor":"Pancreatic","combo":null,"sage":"immune_effector","pharma":"pharma"},{"id":"124","name":"124","title":"Imipridone ONC201 promotes intra-tumoral accumulation of CD3+/NK+ cells that contribute to its anti-tumor efficacy","presenterFirst":"Jessica","presenterLast":"Wagner","presenterInstitution":"Fox Chase Cancer Center","keywords":"Cancer therapy;NA;NA;NA","target":"TRAIL","tumor":"Many","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"5596","name":"5596","title":"Intratumoral administration of a TLR9-adjuvanted nanoparticle cancer vaccine stimulates more effective immunity in both injected and un-injected tumor sites compared to subcutaneous administration","presenterFirst":"Cristiana","presenterLast":"Guiducci","presenterInstitution":"Dynavax Technologies","keywords":"Cancer vaccine;Nanoparticle;Nanoparticle;NA","target":"TLR9","tumor":"Many","combo":null,"sage":"immune_effector","pharma":"pharma"},{"id":"4854","name":"4854","title":"Evaluating HDAC6 as a causal factor in metastatic breast cancer to develop immunotherapy","presenterFirst":"Debarati","presenterLast":"Banik","presenterInstitution":"The George Washington University","keywords":"Epigenetics;Histone deacetylase inhibitor;Histone deacetylase inhibitor;NA","target":"HDAC6","tumor":"Breast","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"3688","name":"3688","title":"Imprime PGG, a novel innate immune therapeutic in phase 2 clinical development, induces mobilization of monocytes and focalized recruitment of innate immune cells to tumor sites","presenterFirst":"Mark","presenterLast":"Uhlik","presenterInstitution":"Biothera Pharmaceuticals, Inc.","keywords":"Innate immunity;Immunohistochemistry;Immunohistochemistry;Imprime PGG","target":"PAMP","tumor":"NA","combo":null,"sage":"immune_effector","pharma":"pharma"},{"id":"4976","name":"4976","title":"Ricolinostat, a selective HDAC6 inhibitor with immunomodulatory properties, has significant anti-melanoma activity in vitro and in vivo","presenterFirst":"Fengdong","presenterLast":"Cheng","presenterInstitution":"The George Washington University","keywords":"Histone deacetylase inhibitor;melanoma;melanoma;NA","target":"HDAC6","tumor":"Melanoma","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"5652","name":"5652","title":"Translational evidence of reactivated innate and adaptive immunity with intratumoral IMO-2125 in combination with systemic checkpoint inhibitors from a Phase I/II study in patients with anti-PD-1 refractory metastatic melanoma","presenterFirst":"Cara","presenterLast":"Haymaker","presenterInstitution":"UT MD Anderson Cancer Center","keywords":"Melanoma/skin cancers;cancer immunotherapy;cancer immunotherapy;Combination therapy","target":"TLR9","tumor":"Melanoma","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"3675","name":"3675","title":"Novel immune oncology strategy for targeted cytotoxic lymphocyte activation","presenterFirst":"Alexander","presenterLast":"Krupnick","presenterInstitution":"University of Virginia","keywords":"Interleukin-2;Lewis lung carcinoma;Lewis lung carcinoma;Tumor microenvironment","target":"IL2","tumor":"NA","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"596","name":"596","title":"eFT508, a potent and highly selective inhibitor of MNK1/2 regulates immune checkpoint and cytokine expression promoting anti-tumor immunity","presenterFirst":"Kevin","presenterLast":"Webster","presenterInstitution":"eFFECTOR Therapeutics","keywords":"Immunotherapy;Immunomodulation;Immunomodulation;MAPK pathway","target":"MNK1/2","tumor":"Colorectal","combo":null,"sage":"immune_effector","pharma":"pharma"},{"id":"1607","name":"1607","title":"Durable efficacy and anti-cancer immunity following intratumoral administration of messenger RNAs encoding IL-36\u03b3, IL-23 and OX40L","presenterFirst":"Josh","presenterLast":"Frederick","presenterInstitution":"Onkaido Therapeutics","keywords":"Immunotherapy;Tumor microenvironment;Tumor microenvironment;RNA","target":"mRNA","tumor":"NA","combo":null,"sage":"immune_effector","pharma":"pharma"},{"id":"1596","name":"1596","title":"Phase I trial of recombinant human Interleukin 15 (rhIL-15) administered as continuous intravenous infusion (CIV) for 10 days (240 hours) in patients with refractory metastatic cancers.","presenterFirst":"Kevin","presenterLast":"Conlon","presenterInstitution":"National Cancer Inst.","keywords":"Immunotherapy;NA;NA;NA","target":"IL15","tumor":"Many","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"4055","name":"4055","title":"Enhancing anti-PD-1 Immune Blockade in Melanoma through Selective Inhibition of Histone Deacetylase 6","presenterFirst":"Tessa","presenterLast":"Knox","presenterInstitution":"The George Washington University","keywords":"Histone deacetylase inhibitor;Melanoma/skin cancers;Melanoma/skin cancers;Antitumor agents","target":"HDAC6","tumor":"Melanoma","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"4691","name":"4691","title":"Polarization of macrophages with STING agonists","presenterFirst":"Kimiora","presenterLast":"Henare","presenterInstitution":"The University of Auckland","keywords":"Macrophages;NA;NA;NA","target":"STING","tumor":"NA","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"CT091","name":"CT091","title":"Safety and pharmacodynamic activity of MEDI9197, a TLR 7/8 agonist, administered intratumorally in subjects with solid tumors","presenterFirst":"Shilpa","presenterLast":"Gupta","presenterInstitution":"Masonic Cancer Center","keywords":"Toll-like receptor 7/8 agonist;NA;NA;NA","target":"TLR7/8","tumor":"Many","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"CT108","name":"CT108","title":"A phase I dose escalation study of intra-tumoral LTX-315 as monotherapy or in combination with either ipilimumab or pembrolizumab in patients with transdermally accessible tumors (NCT01986426)","presenterFirst":"Jean-Francois","presenterLast":"Baurain","presenterInstitution":"Universit\u00e9 catholique de Louvain","keywords":"Combination therapy;Peptides;Peptides;NA","target":"Other","tumor":"Many","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"LB-239","name":"LB-239","title":"Pharmacodynamic changes confirm the mechanism of action mediating SD-101 efficacy, in combination with pembrolizumab, in a phase 1b/2 study in metastatic melanoma (MEL-01)","presenterFirst":"Albert","presenterLast":"Candia","presenterInstitution":"Dynavax Technologies","keywords":"Biomarker;Innate immunity;Innate immunity;NA","target":"TLR9","tumor":"Melanoma","combo":null,"sage":"immune_effector","pharma":"pharma"},{"id":"LB-191","name":"LB-191","title":"Combination checkpoint inhibitor therapy: Anti-PD1 and Beta-alethine lead to complete responses of melanoma in a syngeneic mouse model","presenterFirst":"Floyd","presenterLast":"Taub","presenterInstitution":"FindCure","keywords":"Immunotherapy;Melanoma/skin cancers;Melanoma/skin cancers;NA","target":"Other","tumor":"Melanoma","combo":null,"sage":"immune_effector","pharma":"pharma"}]},{"id":"immunosuppressive","name":"immunosuppressive","presenterLast":"immunosuppressive","children":[{"id":"941","name":"941","title":"CXCL1-CXCR2 Signalling Might Recruit the Bone Marrow-derived Mesenchymal Cells to the Carcinoma-associated Fibroblasts of Gastric Cancer","presenterFirst":"Masakazu","presenterLast":"Yashiro","presenterInstitution":"Osaka City Univ. Grad. School of Medicine","keywords":"Stromal-epithelial interactions;Gastrointestinal cancers: stomach;Gastrointestinal cancers: stomach;CXCR2","target":"CXCR2","tumor":"Gastric","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"942","name":"942","title":"CXCR2 acts as a checkpoint regulator of the pancreatic stellate cells activity within pancreatic cancer tumor microenvironment","presenterFirst":"Mohammad","presenterLast":"Awaji","presenterInstitution":"University of Nebraska Medical Center","keywords":"Chemokine receptor;Fibroblasts;Fibroblasts;NA","target":"CXCR2","tumor":"Pancreatic","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"5005","name":"5005","title":"Inhibition of E-selectin or E-selectin together with CXCR4 re-sensitizes multiple myeloma to treatment","presenterFirst":"Barbara","presenterLast":"Muz","presenterInstitution":"Washington University in St Louis","keywords":"Multiple myeloma;Tumor microenvironment;Tumor microenvironment;Resistance","target":"CXCR4","tumor":"Myeloma","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"2620","name":"2620","title":"Selecting the right chemotherapy partner for checkpoint inhibitors. An in vivo comparison of different drugs and dosages.","presenterFirst":"Francesco","presenterLast":"Bertolini","presenterInstitution":"European Inst. of Oncology","keywords":"Checkpoint;Immunotherapy;Immunotherapy;Vinorelbine","target":"chemo","tumor":"Many","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"1014","name":"1014","title":"Selective impairment of intratumoral regulatory T cells by targeting Ezh2 enhances cancer immunity","presenterFirst":"David","presenterLast":"Wang","presenterInstitution":"University of California, San Francisco","keywords":"Immunotherapy;EZH2;EZH2;TRAMP model","target":"EZH2","tumor":"Many","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"2995","name":"2995","title":"Development of a novel highly potent TLR8 selective agonist for cancer immunotherapy","presenterFirst":"Yuxun","presenterLast":"Wang","presenterInstitution":"Denovo Pharmatech","keywords":"Immunotherapy;Targeted therapy;Targeted therapy;Innate immunity","target":"TLR8","tumor":"NA","combo":null,"sage":"immunosuppressive","pharma":"pharma"},{"id":"4138","name":"4138","title":"In vitro and in vivo models for evaluation of inhibitors of tryptophan dioxygenases","presenterFirst":"Lai-Ming","presenterLast":"Ching","presenterInstitution":"Univ. of Auckland Cancer Society Res. Ctr.","keywords":"Immunomodulation;T cell;T cell;Inhibitors","target":"TDO","tumor":"NA","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"5932","name":"5932","title":"Targeting tumor acidity with the LDHA inhibitor (FX11) and CAIX inhibitor (DH348) overcomes resistance to PD-1 blockade and inhibits metastasis in a Pancreatic Cancer model","presenterFirst":"Arig","presenterLast":"Ibrahim Hashim","presenterInstitution":"Moffitt Cancer Center","keywords":"Pancreatic cancer;Metabolism;Metabolism;T cell","target":"LDHA","tumor":"Pancreatic","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"626","name":"626","title":"BGB324, a selective small molecule inhibitor of receptor tyrosine kinase AXL, abrogates tumor intrinsic and microenvironmental immune suppression and enhances immune checkpoint inhibitor efficacy in lung and mammary adenocarcinoma models","presenterFirst":"Gro","presenterLast":"Gausdal","presenterInstitution":"BerGenBio AS","keywords":"Carcinoma: adenocarcinoma;BGB324;BGB324;EMT","target":"AXL","tumor":"Many","combo":null,"sage":"immunosuppressive","pharma":"pharma"},{"id":"5571","name":"5571","title":"Immune-Checkpoint Inhibition via Enzyme Mediated Degradation of Kynurenine","presenterFirst":"Todd","presenterLast":"Triplett","presenterInstitution":"University of Texas at Austin","keywords":"Immunotherapy;Tumor microenvironment;Tumor microenvironment;Checkpoint","target":"KYN","tumor":"Many","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"5595","name":"5595","title":"HDAC inhibitor Entinostat disrupts function of PMN-MDSC","presenterFirst":"Ayumi","presenterLast":"Hashimoto","presenterInstitution":"The Wistar Institute","keywords":"Histone deacetylase inhibitor;Immunomodulation;Immunomodulation;Immunotherapy","target":"HDAC","tumor":"Many","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"1633","name":"1633","title":"Immunotherapy for malignant mesothelioma that combines a mesothelia-targeted immune-activating protein and CXCL12/CXCR4 blockade","presenterFirst":"Huabiao","presenterLast":"Chen","presenterInstitution":"Massachusetts General Hospital","keywords":"Mesothelioma;CXCR4;CXCR4;Immunotherapy","target":"CXCR4","tumor":"Mesothelioma","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"4942","name":"4942","title":"Small molecule inhibition of CXCR4 mobilizes prostate disseminated tumor cells (DTCs) from the chemoprotective bone marrow niche, thereby sensitizing them to chemotherapy","presenterFirst":"Kenneth","presenterLast":"Valkenburg","presenterInstitution":"Johns Hopkins School of Medicine","keywords":"Bone metastasis;Prostate cancer;Prostate cancer;Chemoresistance","target":"CXCR4","tumor":"Prostate","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"2622","name":"2622","title":"Two new TLR9 agonists for cancer immunotherapy: Combination with checkpoint inhibitors","presenterFirst":"Kerstin","presenterLast":"Kapp","presenterInstitution":"MOLOGEN AG","keywords":"Immunotherapy;Combination therapy;Combination therapy;Checkpoint","target":"TLR9","tumor":"NA","combo":null,"sage":"immunosuppressive","pharma":"pharma"},{"id":"5675","name":"5675","title":"A novel PI3K inhibitor suppresses tumor progression by immune modulation","presenterFirst":"He","presenterLast":"Zhou","presenterInstitution":"Shanghai ChemPartner Co., Ltd.","keywords":"Immunotherapy;Immune response;Immune response;In vivo","target":"PI3K","tumor":"Colorectal","combo":null,"sage":"immunosuppressive","pharma":"pharma"},{"id":"572","name":"572","title":"Inhibition of IDO1 with epacadostat enhances anti-tumor efficacy of PD-1 blockade in a syngeneic glioblastoma (GBM) model","presenterFirst":"David","presenterLast":"Reardon","presenterInstitution":"Dana-Farber Cancer Inst.","keywords":"Immunomodulation;NA;NA;NA","target":"IDO1","tumor":"Glioblastoma","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"5580","name":"5580","title":"Preclinical pharmacodynamics and antitumor activity of AZD4635, a novel adenosine 2A receptor inhibitor that reverses adenosine mediated T cell suppression","presenterFirst":"Alexandra","presenterLast":"Borodovsky","presenterInstitution":"AstraZeneca","keywords":"Immunotherapy;Preclinical;Preclinical;GPCR-G-protein coupled receptor","target":"A2AR","tumor":"Many","combo":null,"sage":"immunosuppressive","pharma":"pharma"},{"id":"5799","name":"5799","title":"Targeting CX3CR1 impairs the reseeding of cancer cells recirculating from metastatic tumors.","presenterFirst":"Chen","presenterLast":"Qian","presenterInstitution":"Drexel University","keywords":"Circulating tumor cells;CX3CR1;CX3CR1;Reseeding","target":"CX3CR1","tumor":"NA","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"4770","name":"4770","title":"Novel CXCR3 allosteric modulators inhibit breast cancer stem cells and metastasis","presenterFirst":"Amy","presenterLast":"Fulton","presenterInstitution":"Univ. of Maryland Greenebaum Cancer Ctr.","keywords":"Chemokine receptor;Metastasis;Metastasis;Breast cancer","target":"CXCR3","tumor":"Breast","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"5570","name":"5570","title":"A novel approach to targeting the IDO/TDO pathway through degradation of the immunosuppressive metabolite kynurenine","presenterFirst":"Mark","presenterLast":"Manfredi","presenterInstitution":"Kyn Therapeutics","keywords":"Immunotherapy;Therapeutic proteins;Therapeutic proteins;Immunostimulation","target":"KYN","tumor":"Many","combo":null,"sage":"immunosuppressive","pharma":"pharma"},{"id":"4706","name":"4706","title":"Spherical nucleic acids targeting toll-like receptor 9 enhance antitumor activity in combination with anti-PD-1 antibody in mouse tumor models","presenterFirst":"SubbaRao","presenterLast":"Nallagatla","presenterInstitution":"Exicure, Inc.","keywords":"Immunotherapy;Checkpoint;Checkpoint;Innate immunity","target":"TLR9","tumor":"Many","combo":null,"sage":"immunosuppressive","pharma":"pharma"},{"id":"2618","name":"2618","title":"Agonist antibodies targeting OX40 and GITR enhance the activity of the IDO1-selective inhibitor epacadostat in preclinical models","presenterFirst":"Holly","presenterLast":"Koblish","presenterInstitution":"Incyte Corporation","keywords":"Immunomodulation;anti-OX40;anti-OX40;anti-GITR","target":"IDO1","tumor":"Many","combo":null,"sage":"immunosuppressive","pharma":"pharma"},{"id":"1691","name":"1691","title":"USP7 inhibitors impair Foxp3+ T regulatory cell function and promote antitumor immunity against solid tumors","presenterFirst":"Suresh","presenterLast":"Kumar","presenterInstitution":"Progenra Inc","keywords":"Cancer immunotherapy;Tumor microenvironment;Tumor microenvironment;Tumor immunity","target":"USP7","tumor":"Lung","combo":null,"sage":"immunosuppressive","pharma":"pharma"},{"id":"4338","name":"4338","title":"The role of IMPACT in survival of cancer cells during tryptophan deprivation by immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO1)","presenterFirst":"Petr","presenterLast":"Tomek","presenterInstitution":"University of Auckland","keywords":"Stress response;tryptophan deprivation;tryptophan deprivation;Bioinformatics","target":"IDO1","tumor":"NA","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"4187","name":"4187","title":"Preclinical evaluation of sulfatinib, a novel angio-immuno kinase inhibitor targeting VEGFR, FGFR1 and CSF1R kinases","presenterFirst":"Weiguo","presenterLast":"Qing","presenterInstitution":"Hutchison MediPharma Limited","keywords":"Vascular endothelial growth factor receptor;Colony stimulating factor 1 receptor;Colony stimulating factor 1 receptor;sulfatinib","target":"CSF1R","tumor":"Colorectal","combo":null,"sage":"immunosuppressive","pharma":"pharma"},{"id":"4564","name":"4564","title":"Synergistic anti-tumor efficacy of combination therapy with APS001F, a cytosine deaminase (CD) expressing <i>Bifidobacterium</i>, 5-fluorocytosine (5-FC) and anti-mPD-1 antibody in syngeneic mice model","presenterFirst":"Koichiro","presenterLast":"Shioya","presenterInstitution":"Anaeropharma Science, Inc.","keywords":"Immunotherapy;5-Fluorouracil;5-Fluorouracil;NA","target":"cytosine_deaminase","tumor":"Colorectal","combo":null,"sage":"immunosuppressive","pharma":"pharma"},{"id":"2169","name":"2169","title":"Pharmacological modulation of CXCL12-CXCR4 intracellular trafficking potentiates the <i>in vitro</i> and <i>in vivo</i> activity of the BET bromodomain inhibitor CPI203 in diffuse large B-cell lymphoma","presenterFirst":"Clara","presenterLast":"Recasens-Zorzo","presenterInstitution":"Institut d'investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS)","keywords":"Drug synergy;CXCR4;CXCR4;c-Myc","target":"CXCR4","tumor":"Lymphoma","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"3970","name":"3970","title":"Targeting the adenosine immunosuppressive pathway for cancer immunotherapy with small molecule agents","presenterFirst":"Michael","presenterLast":"Esquerr\u00e9","presenterInstitution":"EVOTEC","keywords":"Immunomodulation;Immunotherapy;Immunotherapy;Polypharmacology","target":"A2AR","tumor":"NA","combo":null,"sage":"immunosuppressive","pharma":"pharma"},{"id":"638","name":"638","title":"Epigenetic reprograming of immune cells through selective inhibition of HDAC6 reduces suppressive phenotypes and augments anti-tumor properties of T-cells","presenterFirst":"Andressa","presenterLast":"Sodre","presenterInstitution":"NYU Langone Medical Center","keywords":"Immunotherapy;Histone deacetylase inhibitor;Histone deacetylase inhibitor;T cell","target":"HDAC6","tumor":"Melanoma","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"4635","name":"4635","title":"The LSD1 Specific Inhibitor INCB059872 enhances the activity of immune checkpoint blockade by reshaping the myeloid compartment in the syngeneic 4T1 mouse mammary tumor model","presenterFirst":"Thomas","presenterLast":"Condamine","presenterInstitution":"Incyte Corporation","keywords":"Epigenetics;LSD1;LSD1;myeloid cells","target":"LSD1","tumor":"Breast","combo":null,"sage":"immunosuppressive","pharma":"pharma"},{"id":"3684","name":"3684","title":"Inhibition of STAT3 by antisense oligonucleotide treatment decreases the immune suppressive tumor microenvironment in syngeneic and GEM tumor models","presenterFirst":"Rich","presenterLast":"Woessner","presenterInstitution":"AstraZeneca Pharmaceuticals LP","keywords":"STAT3;Tumor microenvironment;Tumor microenvironment;Combination therapy","target":"STAT3","tumor":"Many","combo":null,"sage":"immunosuppressive","pharma":"pharma"},{"id":"1621","name":"1621","title":"Adoptively transferred B cells directly kill tumor cells <i>via</i> the CXCR4/CXCL12 & perforin pathways","presenterFirst":"Qiao","presenterLast":"Li","presenterInstitution":"Univ. of Michigan","keywords":"Breast cancer;B cells;B cells;CXCR4","target":"CXCR4","tumor":"Breast","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"4196","name":"4196","title":"Anti-tumor activity of a TAM kinase-targeting compound in CT-26 syngeneic mouse model","presenterFirst":"Shenshen","presenterLast":"Lai","presenterInstitution":"SignalChem Lifesciences Corporation","keywords":"Tyrosine kinase inhibitor;Combination therapy;Combination therapy;Immunotherapy","target":"TAM","tumor":"Colorectal","combo":null,"sage":"immunosuppressive","pharma":"pharma"},{"id":"4005","name":"4005","title":"HDAC inhibitors regulate M2 tumor-associated macrophage function through histone acetylation","presenterFirst":"Amber","presenterLast":"de Groot","presenterInstitution":"The James Buchanan Brady Urological Institute; Johns Hopkins School of Medicine","keywords":"Macrophages;Prostate cancer;Prostate cancer;Tumor microenvironment","target":"HDAC","tumor":"NA","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"3964","name":"3964","title":"Reducing systemic arginine with arginase (AEB1102) therapy does not suppress the immune response induced by anti-PD-1 and anti-PD-L1, and exerts an additive anti-tumor and synergistic survival benefit","presenterFirst":"Giulia","presenterLast":"Agnello","presenterInstitution":"Aeglea BioTherapeutics Inc.","keywords":"Metabolism;Immunotherapy;Immunotherapy;Anticancer therapy","target":"arginase","tumor":"Many","combo":null,"sage":"immunosuppressive","pharma":"pharma"},{"id":"2680","name":"2680","title":"A novel pro-tumorigenic role for IDO1 in inflammatory neovascularization","presenterFirst":"Alexander","presenterLast":"Muller","presenterInstitution":"Lankenau Inst. for Medical Research","keywords":"Inflammation;Metabolism;Metabolism;Metastasis","target":"IDO1","tumor":"Breast","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"5579","name":"5579","title":"Strategic inhibition of adenosine A2A receptor (A2AR) by CPI-444 improves CD8<sup>+</sup>:Treg ratios and enhances T-cell killing of a HER-2/neu expressing murine tumor","presenterFirst":"Blake","presenterLast":"Scott","presenterInstitution":"Johns Hopkins University School of Medicine","keywords":"Breast cancer;Small molecule inhibitor;Small molecule inhibitor;Vaccines","target":"A2AR","tumor":"Breast","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"4600","name":"4600","title":"Potent and selective C-C chemokine receptor (CCR4) antagonists potentiate anti-tumor immune responses by inhibiting regulatory T cells (T<sub>reg</sub>)","presenterFirst":"Jordan","presenterLast":"Fridman","presenterInstitution":"FLX Bio, Inc.","keywords":"Chemokine receptor;Immunostimulation;Immunostimulation;Immunotherapy","target":"CCR4","tumor":"Many","combo":null,"sage":"immunosuppressive","pharma":"pharma"},{"id":"2629","name":"2629","title":"The synergy between BXCL701, a DPP inhibitor, and immune checkpoint inhibitors discovered using AI and Big Data analytics","presenterFirst":"Luca","presenterLast":"Rastelli","presenterInstitution":"BioXcel","keywords":"Immunotherapy;Tumor microenvironment;Tumor microenvironment;NA","target":"DPP8/9/FAP","tumor":"Prostate","combo":null,"sage":"immunosuppressive","pharma":"pharma"},{"id":"955","name":"955","title":"LY3200882, A Novel, Highly Selective TGF\u03b2RI Small Molecule Inhibitor","presenterFirst":"Kyla","presenterLast":"Driscoll","presenterInstitution":"Eli Lilly","keywords":"TGF-beta;Tumor microenvironment;Tumor microenvironment;Drug discovery","target":"TGFBR","tumor":"Colorectal","combo":null,"sage":"immunosuppressive","pharma":"pharma"},{"id":"2640","name":"2640","title":"Small-molecule inhibitors of CD73, CD39 and A<sub>2a</sub>R: Three anti-cancer targets in the ATP/adenosine signaling pathway","presenterFirst":"Ulrike","presenterLast":"Schindler","presenterInstitution":"Arcus Biosciences Inc.","keywords":"Cancer immunotherapy;ATP;ATP;Immunomodulation","target":"CD73/CD39/A2AR","tumor":"Many","combo":null,"sage":"immunosuppressive","pharma":"pharma"},{"id":"3650","name":"3650","title":"Preclinical evaluation of the PARP inhibitor rucaparib in combination with PD-1 and PD-L1 inhibition in a syngeneic BRCA1 mutant ovarian cancer model","presenterFirst":"Liliane","presenterLast":"Robillard","presenterInstitution":"Clovis Oncology, Inc.","keywords":"PARP;Targeted therapy;Targeted therapy;Immunotherapy","target":"PARP","tumor":"Ovarian","combo":null,"sage":"immunosuppressive","pharma":"pharma"},{"id":"4614","name":"4614","title":"Upregulation of memory T cell population and enhancement of Th1 response by lenvatinib potentiate antitumor activity of PD-1 signaling blockade","presenterFirst":"Yu","presenterLast":"Kato","presenterInstitution":"Eisai.Co.,Ltd.","keywords":"Vascular endothelial growth factor receptor inhibitor;Combination studies;Combination studies;Preclinical","target":"VEGFR","tumor":"Many","combo":null,"sage":"immunosuppressive","pharma":"pharma"},{"id":"2634","name":"2634","title":"EVT801: Standalone cancer immunotherapy in VEGFR3<sup>+</sup> tumors and combination with Immune Checkpoint Therapies in VEGFR3<sup>-</sup> tumors","presenterFirst":"Pierre","presenterLast":"Fons","presenterInstitution":"EVOTEC","keywords":"Vascular endothelial growth factor tyrosine kinase inhibitor;ICT;ICT;Immunotherapy","target":"VEGFR","tumor":"Hepatocarcinoma","combo":null,"sage":"immunosuppressive","pharma":"pharma"},{"id":"2641","name":"2641","title":"AZD4635 A<sub>2A</sub> receptor occupancy in cynomolgus monkey using PET and its application to an Oncology clinical development program","presenterFirst":"Pablo","presenterLast":"Morentin Gutierrez","presenterInstitution":"AstraZeneca","keywords":"Immunomodulation;occupancy;occupancy;PK/PD","target":"A2AR","tumor":"NA","combo":null,"sage":"immunosuppressive","pharma":"pharma"},{"id":"580","name":"580","title":"Nivolumab treatment of metastatic renal cancer patients impairs Tregs and potentiates NK function: the role of CXCR4 inhibition ( \u201c REVOLUTION TRIAL\u201d).","presenterFirst":"Stefania","presenterLast":"Scala","presenterInstitution":"National Cancer Inst. Pascale","keywords":"Renal cell carcinoma;Chemokine receptor;Chemokine receptor;Immunotherapy","target":"CXCR4","tumor":"Kidney","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"5581","name":"5581","title":"Development of 2<sup>nd</sup> generation indoleamine 2,3-dioxygenase 1 (IDO1) selective inhibitors","presenterFirst":"Thomas","presenterLast":"Pesnot","presenterInstitution":"REDX Pharma","keywords":"Immunotherapy;NA;NA;NA","target":"IDO1","tumor":"Many","combo":null,"sage":"immunosuppressive","pharma":"pharma"},{"id":"2639","name":"2639","title":"Development of small molecule selective inhibitors of GCN2 as an immunotherapy aimed at preventing immune escape of tumor cells.","presenterFirst":"Micha\u0142","presenterLast":"Ga\u0142\u0119zowski","presenterInstitution":"Selvita S.A.","keywords":"Kinase inhibitors;Stress response;Stress response;Immunomodulation","target":"GCN2","tumor":"NA","combo":null,"sage":"immunosuppressive","pharma":"pharma"},{"id":"966","name":"966","title":"Phase II clinical trial patient responses to the macrophage activating agent RRx-001 correlate to TGF- \u03b2 pathway activation and markers for fibrosis","presenterFirst":"Saheli","presenterLast":"Jha","presenterInstitution":"Epicentrx","keywords":"Macrophages;Drug delivery;Drug delivery;Chemokines","target":"TGFBR","tumor":"Lung","combo":null,"sage":"immunosuppressive","pharma":"pharma"},{"id":"5578","name":"5578","title":"Small molecule modulators to understand the role of IDO1 and TDO2 in cancer","presenterFirst":"Dhanalakshmi","presenterLast":"Sivanandhan","presenterInstitution":"Jubilant Biosys Ltd.","keywords":"Immunomodulation;TDO2;TDO2;NA","target":"TDO2","tumor":"Breast","combo":null,"sage":"immunosuppressive","pharma":"pharma"},{"id":"4574","name":"4574","title":"Combinatorial strategies of folate receptor-targeted chemotherapy guided by improved understanding of tumor microenvironment and immunomodulation","presenterFirst":"Yingjuan","presenterLast":"Lu","presenterInstitution":"Endocyte","keywords":"Immunomodulation;Folate Receptor;Folate Receptor;Targeted therapy","target":"Many","tumor":"Many","combo":null,"sage":"immunosuppressive","pharma":"pharma"},{"id":"1686","name":"1686","title":"Epigenetic modulation of the tumor microenvironment enhances vaccine induced T cell responses in a murine model of pancreatic cancer","presenterFirst":"Brian","presenterLast":"Christmas","presenterInstitution":"Johns Hopkins University","keywords":"Pancreatic cancer;Epigenetics;Epigenetics;NA","target":"HDAC","tumor":"Pancreatic","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"568","name":"568","title":"Regulatory T cell recruitment limits the effectiveness of checkpoint inhibition for claudin-low breast cancer","presenterFirst":"Sarah","presenterLast":"Vick","presenterInstitution":"University of North Carolina","keywords":"Immunotherapy;NA;NA;NA","target":"CXCR4","tumor":"Breast","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"1642","name":"1642","title":"Evaluation of ENMD-2076 in combination with anti-PD1 in syngeneic cancer models","presenterFirst":"Ken","presenterLast":"Ren","presenterInstitution":"CASI Pharmaceuticals","keywords":"Kinase inhibitors;Combination studies;Combination studies;Syngeneic model","target":"multi","tumor":"Colorectal","combo":null,"sage":"immunosuppressive","pharma":"pharma"},{"id":"5655","name":"5655","title":"Inhibition of CCR2 Potentiates Checkpoint Inhibitor Immunotherapy in Murine Model of Pancreatic Cancer","presenterFirst":"Christine","presenterLast":"Janson","presenterInstitution":"ChemoCentryx","keywords":"Chemokines;Pancreatic cancer;Pancreatic cancer;Immunotherapy","target":"CCR2","tumor":"Pancreatic","combo":null,"sage":"immunosuppressive","pharma":"pharma"},{"id":"5336","name":"5336","title":"Characterization of selective covalent inhibitors of USP7","presenterFirst":"Feng","presenterLast":"Wang","presenterInstitution":"Progenra Inc","keywords":"Ubiquitination;Cancer;Cancer;Immunomodulation","target":"USP7","tumor":"NA","combo":null,"sage":"immunosuppressive","pharma":"pharma"},{"id":"4572","name":"4572","title":"Characterization of the potent and selective A<sub>2a</sub>R antagonist AB928 for the treatment of cancer","presenterFirst":"Matt","presenterLast":"Walters","presenterInstitution":"Arcus Biosciences Inc.","keywords":"Cancer immunotherapy;ATP;ATP;Immunomodulation","target":"A2AR","tumor":"Many","combo":null,"sage":"immunosuppressive","pharma":"pharma"},{"id":"95","name":"95","title":"Targeting BRD4 overcomes cetuximab resistance in HNSCC","presenterFirst":"Neil","presenterLast":"Bhola","presenterInstitution":"University of California San Francisco","keywords":"Head and neck squamous cell carcinoma cell line;cetuximab;cetuximab;Receptor tyrosine kinase","target":"BRD4","tumor":"Head_Neck","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"2811","name":"2811","title":"Comparative study of anti-PD1 and CSF1R inhibition on tumor-infiltrating lymphocytes and macrophage populations across a panel of syngeneic tumor models","presenterFirst":"Yuki","presenterLast":"Kato Maves","presenterInstitution":"Crown Biosciences","keywords":"Immunotherapy;Macrophages;Macrophages;NA","target":"CSF1R","tumor":"Many","combo":null,"sage":"immunosuppressive","pharma":"pharma"},{"id":"2222","name":"2222","title":"Sildenafil suppresses inflammation-driven colorectal cancer in mice.","presenterFirst":"Bianca","presenterLast":"Islam","presenterInstitution":"Augusta University, Georgia Cancer Center","keywords":"Colon cancer;Inflammation;Inflammation;Therapeutics","target":"PDE5","tumor":"Colorectal","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"788","name":"788","title":"Less is more: macrophage depletion via CSF1/CSF1R pathway improves anti-VEGF therapy after adaptive resistance","presenterFirst":"Yasmin","presenterLast":"Lyons","presenterInstitution":"University of Texas MD Anderson Cancer Center","keywords":"Macrophages;Antiangiogenic agents;Antiangiogenic agents;Resistance","target":"CSF1R","tumor":"Ovarian","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"3704","name":"3704","title":"Targeting M2-Tumor Associated Macrophages (M2-TAMs) using enriched glycoproteins in Lethal Prostate Cancer","presenterFirst":"Jelani","presenterLast":"Zarif","presenterInstitution":"Johns Hopkins University School of Medicine","keywords":"Macrophages;NA;NA;NA","target":"NA","tumor":"Prostate","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"3021","name":"3021","title":"CCR5 Inhibition: macrophage repolarization therapy for colorectal cancer","presenterFirst":"Niels","presenterLast":"Halama","presenterInstitution":"National Ctr. for Tumor Diseases","keywords":"Immunotherapy;Colorectal cancer;Colorectal cancer;Metastasis","target":"CCR5","tumor":"Colorectal","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"4076","name":"4076","title":"A novel prodrug of indoximod with enhanced pharmacokinetic properties","presenterFirst":"Mario","presenterLast":"Mautino","presenterInstitution":"NewLink Genetics Corp.","keywords":"Immunostimulation;Drug discovery;Drug discovery;Checkpoint","target":"IDO1","tumor":"NA","combo":null,"sage":"immunosuppressive","pharma":"pharma"},{"id":"4964","name":"4964","title":"Structure, in vitro biology and in vivo pharmacodynamic characterization of a novel clinical IDO1 inhibitor","presenterFirst":"John","presenterLast":"Hunt","presenterInstitution":"Bristol-Myers Squibb Co.","keywords":"Immunotherapy;NA;NA;NA","target":"IDO2","tumor":"NA","combo":null,"sage":"immunosuppressive","pharma":"pharma"},{"id":"5593","name":"5593","title":"Inhibition of A2AR induces anti-tumor immunity alone and in combination with anti-PD-L1 in preclinical and clinical studies.","presenterFirst":"Stephen","presenterLast":"Willingham","presenterInstitution":"Corvus Pharmaceuticals","keywords":"Immunotherapy;Biomarker;Biomarker;Tumor microenvironment adenosine","target":"A2AR","tumor":"Many","combo":null,"sage":"immunosuppressive","pharma":"pharma"},{"id":"3332","name":"3332","title":"Aberrant expression of CSF1R in melanoma is driven through an endogenous viral promoter and it contributes to malignant growth and the acquisition of resistance against BRAF inhibition","presenterFirst":"Orsolya","presenterLast":"Giricz","presenterInstitution":"Albert Einstein College of Medicine","keywords":"Melanoma/skin cancers;Resistance;Resistance;NA","target":"CSF1R","tumor":"Melanoma","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"903","name":"903","title":"CXCR4 and CXCR7 play distinct and overlapping roles in prostate cancer dissemination to bone","presenterFirst":"Sounak","presenterLast":"Roy","presenterInstitution":"Johns Hopkins University","keywords":"Genitourinary cancers: prostate;Bone metastasis;Bone metastasis;Chemokine receptor","target":"CXCR4","tumor":"Prostate","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"2647","name":"2647","title":"TGF-\u03b2 type I receptor inhibitor (TEW-7197) diminishes myeloma progression by multiple immunomodulatory mechanisms in combination with ixazomib.","presenterFirst":"Byung-Gyu","presenterLast":"Kim","presenterInstitution":"Case Western Reserve University","keywords":"TGF-beta;Tumor microenvironment;Tumor microenvironment;NA","target":"TGFBR","tumor":"Myeloma","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"1627","name":"1627","title":"Enhancement of anti-cancer immunity by OMX, a novel oxygen carrier immunotherapeutic that ameliorates the hypoxic tumor microenvironment","presenterFirst":"Kevin","presenterLast":"Leong","presenterInstitution":"Omniox, Inc.","keywords":"Hypoxia;Combination therapy;Combination therapy;Immunotherapy","target":"Other","tumor":"Many","combo":null,"sage":"immunosuppressive","pharma":"pharma"},{"id":"947","name":"947","title":"CXCR4 in combination with immune check point inhibition in ovarian cancer mouse model demonstrates potential for novel therapeutic strategies","presenterFirst":"Kristen","presenterLast":"Starbuck","presenterInstitution":"Roswell Park Cancer Institute","keywords":"Chemokines;NA;NA;NA","target":"CXCR4","tumor":"Ovarian","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"5598","name":"5598","title":"Adenosine signaling through A2AR limits the efficacy of anti-CTLA4 and chemotherapy in preclinical models","presenterFirst":"Stephen","presenterLast":"Willingham","presenterInstitution":"Corvus Pharmaceuticals","keywords":"Immunotherapy;Adenosine CD73 CD39;Adenosine CD73 CD39;Chemotherapy","target":"A2AR","tumor":"Many","combo":null,"sage":"immunosuppressive","pharma":"pharma"},{"id":"956","name":"956","title":"Novel oral small molecule CXCR4 inhibitor improves activity of immune checkpoint blockade in ovarian cancer mouse model","presenterFirst":"Kristen","presenterLast":"Starbuck","presenterInstitution":"Roswell Park Cancer Institute","keywords":"Ovarian cancer;NA;NA;NA","target":"CXCR4","tumor":"Ovarian","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"LB-197","name":"LB-197","title":"First-in-class TREM-1 inhibitors attenuate tumor growth and angiogenesis by suppressing intratumoral macrophage infiltration and activation in preclinical models of lung and pancreatic cancer","presenterFirst":"Alexander","presenterLast":"Sigalov","presenterInstitution":"SignaBlok, Inc.","keywords":"Macrophage Infiltration and Activation;TREM-1 Inhibitors;TREM-1 Inhibitors;NA","target":"TREM-1","tumor":"Lung","combo":null,"sage":"immunosuppressive","pharma":"pharma"},{"id":"LB-193","name":"LB-193","title":"Protein phosphatase 2A inhibition,with a novel small molecule inhibitor, LB-100, achieves durable immune-mediated antitumor activity when combined with PD1 blockade in a preclinical model","presenterFirst":"Winson","presenterLast":"Ho","presenterInstitution":"National Institutes of Health","keywords":"Protein phosphatase;NA;NA;NA","target":"PP2A","tumor":"Colorectal","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"CT116","name":"CT116","title":"BMS-986205, an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamic (PD) activity, alone and in combination with nivolumab (nivo) in advanced cancers in a phase 1/2a trial","presenterFirst":"Lillian","presenterLast":"Siu","presenterInstitution":"Princess Margaret Cancer Centre","keywords":"IDO1;BMS-986205;BMS-986205;NA","target":"IDO1","tumor":"Many","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"CT119","name":"CT119","title":"CPI-444, an oral adenosine A2a receptor (A2aR) antagonist, demonstrates clinical activity in patients with advanced solid tumors","presenterFirst":"Leisha","presenterLast":"Emens","presenterInstitution":"Johns Hopkins University","keywords":"Phase 1;Antitumor activity;Antitumor activity;NA","target":"A2AR","tumor":"Many","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"LB-190","name":"LB-190","title":"Combination of pembrolizumab and metronomic cyclophosphamide in patients with advanced sarcomas: a french sarcoma group study","presenterFirst":"ANTOINE","presenterLast":"ITALIANO","presenterInstitution":"INSTITUT BERGONIE","keywords":"Immunotherapy;NA;NA;NA","target":"chemo","tumor":"Sarcoma","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"CT056","name":"CT056","title":"A Phase Ib/II randomised open label study of BGB324 in combination with pembrolizumab or dabrafenib/trametinib compared to pembrolizumab or dabrafenib/trametinib alone, in patients with advanced non-resectable (Stage IIIc) or metastatic (Stage IV) melanom","presenterFirst":"Oddbjorn","presenterLast":"Straume","presenterInstitution":"Haukeland Univ. Hospital","keywords":"Immunotherapy;Combination studies;Combination studies;NA","target":"AXL","tumor":"Melanoma","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"CT089","name":"CT089","title":"IPI-549-01 - A Phase 1/1b, first-in-human study of IPI-549, a PI3K-\u03b3 inhibitor, as monotherapy and in combination with nivolumab in patients with advanced solid tumors","presenterFirst":"Jedd","presenterLast":"Wolchok","presenterInstitution":"Memorial Sloan Kettering Cancer Center","keywords":"checkpoint resistance;tumor microenvironment;tumor microenvironment;NA","target":"PI3K","tumor":"Many","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"CT117","name":"CT117","title":"Interim analysis of the Phase 2 clinical trial of the IDO pathway inhibitor indoximod in combination with pembrolizumab for patients with advanced melanoma","presenterFirst":"Yousef","presenterLast":"Zakharia","presenterInstitution":"University of Iowa","keywords":"IDO;NA;NA;NA","target":"IDO1","tumor":"Many","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"LB-212","name":"LB-212","title":"Antioxidant therapy reprograms macrophages from protumor M2 to antitumor M1","presenterFirst":"Brandon","presenterLast":"Griess","presenterInstitution":"Univ. of Nebraska Medical Ctr.","keywords":"Polarization;Breast cancer;Breast cancer;NA","target":"Other","tumor":"Many","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"LB-199","name":"LB-199","title":"Imprime PGG modulates immunosuppressive myeloid components of the tumor microenvironment and drives enhanced antitumor efficacy in combination with checkpoint inhibitor therapies","presenterFirst":"Adria","presenterLast":"Jonas","presenterInstitution":"Biothera pharmaceuticals","keywords":"Tumor microenvironment;Immunomodulation;Immunomodulation;NA","target":"PAMP","tumor":"Many","combo":null,"sage":"immunosuppressive","pharma":"pharma"}]}]}
